enGene Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENGN Nasdaq 2836 www.engene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for enGene Therapeutics Inc.

enGene Announces Name Change to enGene Therapeutics Inc. - Apr 7th, 2026 6:00 am
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference - Mar 15th, 2026 3:33 pm
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - Mar 15th, 2026 2:37 pm
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update - Mar 15th, 2026 1:03 pm
enGene Reports First Quarter 2026 Financial Results and Provides Business Update - Mar 9th, 2026 5:00 am
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference - Feb 27th, 2026 5:16 pm
enGene to Participate in Upcoming Investor Conferences - Feb 20th, 2026 6:00 am
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN) - Feb 16th, 2026 5:04 am
enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment - Feb 12th, 2026 3:02 am
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 4th, 2026 6:00 am
Both private equity firms who control a good portion of enGene Holdings Inc. (NASDAQ:ENGN) along with institutions must be dismayed after last week's 16% decrease - Feb 2nd, 2026 3:50 am
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls - Jan 30th, 2026 7:54 am
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. - Jan 20th, 2026 3:35 pm
enGene Reports Full Year 2025 Financial Results and Provides Business Update - Dec 22nd, 2025 2:03 pm
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Dec 16th, 2025 8:00 am
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial - Dec 4th, 2025 8:09 pm
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness - Dec 2nd, 2025 5:30 am
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference - Nov 25th, 2025 5:30 am
enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results - Nov 13th, 2025 1:17 am
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants - Nov 12th, 2025 10:27 pm